Logo-ps

Submitted: 29 Dec 2025
Revision: 14 Apr 2026
Accepted: 15 Apr 2026
ePublished: 08 Jun 2026
EndNote EndNote

(Enw Format - Win & Mac)

BibTeX BibTeX

(Bib Format - Win & Mac)

Bookends Bookends

(Ris Format - Mac only)

EasyBib EasyBib

(Ris Format - Win & Mac)

Medlars Medlars

(Txt Format - Win & Mac)

Mendeley Web Mendeley Web
Mendeley Mendeley

(Ris Format - Win & Mac)

Papers Papers

(Ris Format - Win & Mac)

ProCite ProCite

(Ris Format - Win & Mac)

Reference Manager Reference Manager

(Ris Format - Win only)

Refworks Refworks

(Refworks Format - Win & Mac)

Zotero Zotero

(Ris Format - Firefox Plugin)

Pharm Sci. 2026;32(4): 632-639.
doi: 10.34172/ps.43631
  Abstract View: 465
  PDF Download: 111

Original Article

Hematologic Toxicity Patterns and Prognostic Value of Complete Blood Count in Advanced HR-positive/HER2-negative Breast Cancer Treated with Palbociclib plus Letrozole: A Real-World Single-Center Study

Adnan Mustafa Isamail 1* ORCID logo, Eman Saadi Saleh 2 ORCID logo, Ahmed Zuhair Alsammarraie 3 ORCID logo

1 Department of Clinical Laboratory Sciences, College of Pharmacy, University of Tikrit, Salah Aldeen, Iraq
2 Department of Clinical Laboratory Sciences, College of Pharmacy, University of Baghdad, Baghdad, Iraq
3 Oncology Teaching Hospital, Bab Al-muadham, Baghdad, Iraq
*Corresponding Author: Adnan Mustafa Ismail, Email: Adnan.m.ismail@tu.edu.iq

Abstract

Introduction: The prognostic value of complete blood count (CBC) parameters in patients with advanced HR-positive/HER2-negative breast cancer receiving palbociclib plus letrozole remains unclear. This study aimed to characterize hematologic toxicity patterns associated with treatment response and survival in real-world setting.

Methods: This prospective single-center study included 80 women receiving palbociclib plus letrozole. CBC was collected at baseline and after each of six cycles. Toxicities were graded by CTCAE v5.0. Analyses were descriptive with repeated-measures ANOVA, and ROC curve analysis.

Results: Most hematologic toxicities were grade 1-2; grade 3-4 neutropenia was uncommon and no febrile events occurred. Higher mean WBC and RBC counts during treatment were significantly associated with non-response and shorter progression-free survival (PFS).

Conclusion: Palbociclib plus letrozole showed a manageable safety profile without cumulative hematologic toxicity. Higher on-treatment WBC and RBC counts are prognostic for poorer outcomes. Routine CBC monitoring may offer a low-cost tool to identify patients at risk for treatment failure.


First Name
Last Name
Email Address
Comments
Security code


Abstract View: 465

Your browser does not support the canvas element.

PDF Download: 111

Your browser does not support the canvas element.